Thymidine, q.v., analog. Preferentially incorporated into cellular DNA in place of thymidine during replication causing increased radiosensitivity of the cell. Prepn and inhibition of DNA biosynthesis: R. E. Beltz, D. W. Visser, J. Am. Chem. Soc. 77, 736 (1955); T. J. Bardos et al., ibid. 4279. X-ray crystallography: J. Iball et al., Nature 209, 1230 (1966). HPLC determn in plasma: D. A. Ganes, J. G. Wagner, J. Chromatogr. 432, 233 (1988). Clinical studies in brain tumors: H. S. Greenberg et al., Neurology 44, 1715 (1994); T. L. Phillips et al., Int. J. Radiat. Oncol. Biol. Phys. 21, 709 (1991). Review of radiobiology and therapeutic potential: T. J. Kinsella et al., ibid. 10, 1399-1406 (1984); of genetic toxicology: S. M. Morris, Mutat. Res. 258, 161-188 (1991); of role in management of CNS tumors: A. Freese et al., J. Neuro-Oncol. 20, 81-95 (1994). Series of reviews on diagnostic and research use: F. Dolbeare, Histochem. J. 27, 339-369, 923-964 (1995); 28, 531-575 (1996).
Antineoplastic adjunct (radiosensitizer); diagnostic aid (tumor cell label for cytokinetic analysis).
Antineoplastic Adjunct; Radiosensitizer; Diagnostic Aid